Nonsteroidal anti-inflammatory drugs prevent gastric cancer associated with the use of proton pump inhibitors after
COX2 inhibitors
Helicobacter pylori
NSAIDs
gastric cancer
proton pump inhibitor
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
16
10
2020
revised:
19
03
2021
accepted:
23
05
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
16
7
2021
Statut:
epublish
Résumé
Proton pump inhibitors (PPIs) are a potential cause of gastric carcinogenesis after A multicenter retrospective cohort study was conducted. Patients who used a PPI (≥30 days) after During the mean follow-up period of 2.38 years, 1.13% (31/2431) of all patients developed gastric cancer. The cumulative incidence of gastric cancer in PPI users was 0.25% at 1 year, 0.51% at 3 years, and 1.09% at 5 years in the NSAID users and 0.89% at 1 year, 2.32% at 3 years, and 3.61% at 5 years in nonusers. NSAIDs were associated with a lower gastric cancer risk (adjusted hazard ratio = 0.28, NSAIDs were associated with a 60% decrease in the gastric cancer incidence in
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Proton pump inhibitors (PPIs) are a potential cause of gastric carcinogenesis after
METHODS
METHODS
A multicenter retrospective cohort study was conducted. Patients who used a PPI (≥30 days) after
RESULTS
RESULTS
During the mean follow-up period of 2.38 years, 1.13% (31/2431) of all patients developed gastric cancer. The cumulative incidence of gastric cancer in PPI users was 0.25% at 1 year, 0.51% at 3 years, and 1.09% at 5 years in the NSAID users and 0.89% at 1 year, 2.32% at 3 years, and 3.61% at 5 years in nonusers. NSAIDs were associated with a lower gastric cancer risk (adjusted hazard ratio = 0.28,
CONCLUSION
CONCLUSIONS
NSAIDs were associated with a 60% decrease in the gastric cancer incidence in
Identifiants
pubmed: 34263071
doi: 10.1002/jgh3.12583
pii: JGH312583
pmc: PMC8264245
doi:
Types de publication
Journal Article
Langues
eng
Pagination
770-777Informations de copyright
© 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Gut. 2016 Sep;65(9):1439-46
pubmed: 26935876
Gastric Cancer. 2004;7(1):9-16
pubmed: 15052434
J Clin Gastroenterol. 1998;27 Suppl 1:S47-52
pubmed: 9872498
J Clin Oncol. 2010 Jun 20;28(18):2952-7
pubmed: 20479409
Am J Epidemiol. 2009 Aug 15;170(4):507-14
pubmed: 19584132
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Gut. 2018 Oct;67(10):1908-1910
pubmed: 29273641
BMJ. 2005 Jun 11;330(7504):1366
pubmed: 15947398
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Lancet. 2002 Jan 5;359(9300):14-22
pubmed: 11809181
Gastroenterology. 2016 May;150(5):1113-1124.e5
pubmed: 26836587
Gut. 2018 Jan;67(1):28-35
pubmed: 29089382
Clin Cancer Res. 2004 Dec 1;10(23):8105-13
pubmed: 15585646
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1706-1719.e5
pubmed: 27211501
Arch Intern Med. 2008 Jun 9;168(11):1219-24
pubmed: 18541831
Int J Cancer. 2010 Mar 15;126(6):1467-73
pubmed: 19711347